Metropolis Healthcare Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsInterim Dividend of 50% at ₹1/Share	19-May-2026	19-May-2026
Bonus3:1	20-Mar-2026	20-Mar-2026
DividendsInterim Dividend of 200% at ₹4/Share	11-Nov-2025	11-Nov-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
HDFC Focused Fund - Regular Plan - Growth	68.00 Lac	68.00 Lac no change
HDFC Flexi Cap Fund - Growth	65.00 Lac	65.00 Lac no change
Kotak Small Cap Fund - Growth	63.80 Lac	63.80 Lac no change
Franklin India Small Cap Fund - Growth	46.78 Lac	50.24 Lac (7.4%)
Nippon India Small Cap Fund - Growth	45.81 Lac	45.81 Lac no change

Sarathi Research

7 Oct • 5:24 AM · SEBI-Registered Analyst

Metropolis Healthcare Falls Despite Beating Q2 Estimates

METROPOLIS

Metropolis Healthcare shares slipped nearly 3% to Rs 537.60 on Tuesday, even as the diagnostics chain posted what was widely described as a positive set of September quarter numbers, a case of a stock selling off on good news because expectations had already run ahead of results. The stock opened weak and stayed under pressure through the session despite Q2 FY27 earnings beating what analysts had been looking for. This follows a strong run through the year, Metropolis had delivered 17% revenue growth to around Rs 450 crore in the June quarter alongside guidance that exceeded expectations, so the bar going into this print was already high. When a stock has rallied hard into an earnings date, even a genuinely good quarter can trigger profit booking if the numbers don't clear an increasingly demanding bar. Metropolis operates one of India's larger diagnostics networks, built on core pathology testing and a faster growing wellness segment. Investors here watch realisation per test and the mix shift toward higher margin wellness packages, since that determines whether revenue growth converts into profit growth. Today's reaction suggests the street wants that margin trajectory to sustain, not just top line growth. The stock has traded between Rs 412.25 and Rs 609.05 over the past 52 weeks, and carries a market capitalisation of around Rs 11,465 crore. Trading well off its 52-week high even after a strong year of growth, valuation remains a key swing factor for how the market treats every subsequent quarter. Disclosure: Palash Kag, Proprietor, Sarathi Research (SEBI Reg. No. INH000012740). No position held in Metropolis Healthcare. This article is for educational and informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Please consult a registered advisor before making investment decisions.

Sohrab Shaikh (SEBI RA)

25 Sep • 2:14 PM · SEBI-Registered Analyst

Dr. Lal PathLabs gets nod to acquire 70% stake in SN Genelab

Dr. Lal PathLabs has received approval for the acquisition of 70% stake in SN Genelab (SN Gene) from its existing Shareholders. Post acquisition, SN Gene shall become a Subsidiary of the Company. The Board of Directors in their meeting held on September 24, 2026, inter-alia considered and approved the same. The object of acquisition is to strengthen the company’s expertise in genomics and broaden its portfolio of advanced diagnostic services. The transaction will be completed by November 30, 2026. Impact : The acquisition of a 70% stake in SN Genelab is expected to yield a net-positive long-term structural impact for Dr. Lal PathLabs, despite causing minor short-term margin compression and initial EPS dilution. The integration expands Dr. Lal's high-end genomics and molecular oncology portfolio while strengthening its geographic footprint in Western India and the UAE. View : It has traditionally been dominant in North India, SN Genelab provides it with ready-made premium infrastructure in Gujarat (Surat and Ahmedabad) alongside international testing hubs in Dubai and Ras Al Khaimah. Unlike many diagnostic startups that operate at a loss or at break-even (such as Core Diagnostics, which Metropolis acquired in late 2024 at 2.2x sales while at EBITDA break-even), SN Genelab is highly profitable. It maintains a robust EBITDA margin of 30%, meaning it will immediately contribute profitable cash flow to Dr. Lal PathLabs once consolidated. Disclosure : I do not hold any position in the mentioned stock. Disclaimer : Investment in securities are subject to market risk. This is only for educational purpose.

LALPATHLAB

Sunil Kotak

23 Sep • 12:03 PM · SEBI-Registered Analyst

Crisil revises Metropolis outlook to positive

Crisil revises Metropolis outlook to positive reaffirms 'AA-' rating

METROPOLIS

SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 The rating agency also reaffirmed its short-term bank facility rating at 'Crisil A1+', according to a note from Crisil Ratings. Crisil said the outlook revision reflects the expected improvement in organic revenue growth, profitability, and cash accruals, along with a meaningful turnaround in its recent acquisition, Core Diagnostics Pvt Ltd. Higher utilisation of the expanded laboratory network, a favourable test mix, and better profitability at Core Diagnostics are expected to support healthy operating margins over the medium term, the agency noted. According to the rating agency, MHL's revenue increased 24 per cent to ₹1,646 crore in FY26, driven by higher patient volumes and specialised diagnostic and wellness tests under the 'TruHealth' brand. Revenue growth continued at a healthy 16.6 per cent in the first quarter of FY27. Recent acquisitions also expanded the company's footprint in north India, raising its contribution to domestic revenue to 17 per cent from 9 per cent, it said. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

Pyrifera Investment Advisors

9 Sep • 3:54 AM · SEBI-Registered Analyst

Metropolis Healthcare Restructures MQSPL

Metropolis Healthcare Limited has announced a strategic restructuring of its subsidiary, Metropolis Quality Solutions Private Limited (MQSPL), bringing in external capital and expertise to scale its External Quality Assessment Services (EQAS) vertical. Key Highlights: Stake Dilution: Metropolis’ ownership in MQSPL will be diluted from 100% to a majority stake of 54.90% on a fully diluted basis. New Strategic Investors: Medsource Ozone Biomedicals will invest ₹1.10 crore (acquiring a 30.60% stake), and Dr. Puneet Kumar Nigam will invest ₹16 lakh (acquiring a 14.50% stake), bringing total external capital infusion to ₹1.26 crore. Strategic Rationale: Capital-Efficient Scaling: By transitioning MQSPL into a collaborative joint structure, Metropolis can accelerate the growth of its specialized EQAS business without bearing the full capital strain. Operational Synergies: The partnership secures vital clinical, operational, and product development backing, leveraging Medsource’s strong manufacturing and distribution pipeline to expand MQSPL’s market reach. Market Implications: This minor equity dilution has no material impact on Metropolis’ consolidated earnings but serves as a positive strategic move. It allows the parent company to maintain majority control while de-risking the business model and fostering subsidiary-level value creation, keeping management sharply focused on its core diagnostics operations.

METROPOLIS

THREETREND RESEARCH

6 Sep • 2:19 PM · SEBI-Registered Analyst

Breakout Point as Support chart example chart

METROPOLIS

When a stock breaks out above an important resistance level, that previous resistance can often become a new support zone. This happens because buyers who missed the initial breakout may enter during a retest, while existing buyers defend the breakout level. A successful retest and bounce from the breakout point strengthens the validity of the breakout and can indicate continued bullish momentum. The higher the volume during the breakout, the more significant the level can become. However, if price falls decisively below the breakout zone and fails to reclaim it, the breakout may be considered failed. In simple terms: Resistance → Breakout → Retest → Previous resistance becomes support → Bounce = bullish continuation.

Dhwani Patel

23 Aug • 9:08 AM · SEBI-Registered Analyst

Metropolis Healthcare Shows Stronger Earnings Momentum

METROPOLIS

is showing a meaningful improvement in its fundamental trajectory, supported by stronger revenue growth, better operating leverage and healthy profitability across its diagnostics business. The latest Q1 FY27 numbers also continued the growth trend, with consolidated revenue rising to roughly ₹455 crore and net profit reaching nearly ₹57 crore. Overall, the combination of higher testing volumes, specialty diagnostics, expanding reach and improving margins provides a constructive fundamental backdrop for the stock. On the technical front, Metropolis Healthcare is developing a well-defined ascending triangle on the daily chart, a structure that generally reflects a gradual shift in control towards buyers. The stock has repeatedly approached the ₹580–₹595 region, creating a relatively flat resistance zone, while the successive higher lows form a clearly rising support trendline. This combination suggests that sellers are finding it increasingly difficult to push the price back to previous lows, while buyers continue to absorb supply on declines. The recent move towards the upper boundary, accompanied by a strong daily advance, keeps the setup constructive and raises the probability of a breakout attempt. A sustained close above ₹595 would provide confirmation of the pattern and could open the way towards the ₹640–₹660 zone, subject to momentum and volume confirmation. On the downside, ₹535–₹540 remains an important immediate support area, while the rising trendline around the ₹450–₹460 region represents the broader structural support.

Metropolis Healthcare Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Metropolis Healthcare Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Metropolis Healthcare Ltd.?

What is the market cap of Metropolis Healthcare Ltd.?

Should I buy Metropolis Healthcare Ltd. stock now?

What is the 52 week high and low of Metropolis Healthcare Ltd.?

Is the Metropolis Healthcare Ltd. stock good to buy?

Is Metropolis Healthcare Ltd. a good buy for the long term?

Is Metropolis Healthcare Ltd. overvalued or undervalued?

What is the PE and PB ratio of Metropolis Healthcare Ltd.?